International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers

Alberto Biggi; Andrea Gallamini; Stephane Chauvie; Martin Hutchings; Lale Kostakoglu; Michele Gregianin; Michel Meignan; Bogdan Malkowski; Michael S Hofman; Sally F Barrington

doi:10.2967/jnumed.112.110890

International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers

Alberto Biggi
, Andrea Gallamini
, Stephane Chauvie
, Martin Hutchings
, Lale Kostakoglu
, Michele Gregianin
, Michel Meignan
, Bogdan Malkowski
, Michael S Hofman
, Sally F Barrington

274 Citationer (Scopus)

Abstract

At present, there are no standard criteria that have been validated for interim PET reporting in lymphoma. In 2009, an international workshop attended by hematologists and nuclear medicine experts in Deauville, France, proposed to develop simple and reproducible rules for interim PET reporting in lymphoma. Accordingly, an international validation study was undertaken with the primary aim of validating the prognostic role of interim PET using the Deauville 5-point score to evaluate images and with the secondary aim of measuring concordance rates among reviewers using the same 5-point score. This paper focuses on the criteria for interpretation of interim PET and on concordance rates.

Originalsprog	Engelsk
Tidsskrift	Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Vol/bind	54
Udgave nummer	5
Sider (fra-til)	683-90
Antal sider	8
ISSN	0161-5505
DOI	https://doi.org/10.2967/jnumed.112.110890
Status	Udgivet - maj 2013

Adgang til dokumentet

10.2967/jnumed.112.110890

Citationsformater

Biggi, A., Gallamini, A., Chauvie, S., Hutchings, M., Kostakoglu, L., Gregianin, M., Meignan, M., Malkowski, B., Hofman, M. S., & Barrington, S. F. (2013). International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(5), 683-90. https://doi.org/10.2967/jnumed.112.110890

International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. / Biggi, Alberto; Gallamini, Andrea; Chauvie, Stephane et al.
I: Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Bind 54, Nr. 5, 05.2013, s. 683-90.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Biggi, A, Gallamini, A, Chauvie, S, Hutchings, M, Kostakoglu, L, Gregianin, M, Meignan, M, Malkowski, B, Hofman, MS & Barrington, SF 2013, 'International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, bind 54, nr. 5, s. 683-90. https://doi.org/10.2967/jnumed.112.110890

Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M et al. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2013 maj;54(5):683-90. doi: 10.2967/jnumed.112.110890

@article{f4b210fd6e684225b5894eb180b1472a,

title = "International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers",

abstract = "At present, there are no standard criteria that have been validated for interim PET reporting in lymphoma. In 2009, an international workshop attended by hematologists and nuclear medicine experts in Deauville, France, proposed to develop simple and reproducible rules for interim PET reporting in lymphoma. Accordingly, an international validation study was undertaken with the primary aim of validating the prognostic role of interim PET using the Deauville 5-point score to evaluate images and with the secondary aim of measuring concordance rates among reviewers using the same 5-point score. This paper focuses on the criteria for interpretation of interim PET and on concordance rates.",

keywords = "Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Consensus, Dacarbazine, Doxorubicin, Hodgkin Disease, Humans, Image Interpretation, Computer-Assisted, Information Storage and Retrieval, Internationality, Multimodal Imaging, Neoplasm Staging, Positron-Emission Tomography, Research Report, Tomography, X-Ray Computed, Vinblastine",

author = "Alberto Biggi and Andrea Gallamini and Stephane Chauvie and Martin Hutchings and Lale Kostakoglu and Michele Gregianin and Michel Meignan and Bogdan Malkowski and Hofman, \{Michael S\} and Barrington, \{Sally F\}",

year = "2013",

month = may,

doi = "10.2967/jnumed.112.110890",

language = "English",

volume = "54",

pages = "683--90",

journal = "Journal of nuclear medicine : official publication, Society of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine Inc.",

number = "5",

}

TY - JOUR

T1 - International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma

T2 - interpretation criteria and concordance rate among reviewers

AU - Biggi, Alberto

AU - Gallamini, Andrea

AU - Chauvie, Stephane

AU - Hutchings, Martin

AU - Kostakoglu, Lale

AU - Gregianin, Michele

AU - Meignan, Michel

AU - Malkowski, Bogdan

AU - Hofman, Michael S

AU - Barrington, Sally F

PY - 2013/5

Y1 - 2013/5

N2 - At present, there are no standard criteria that have been validated for interim PET reporting in lymphoma. In 2009, an international workshop attended by hematologists and nuclear medicine experts in Deauville, France, proposed to develop simple and reproducible rules for interim PET reporting in lymphoma. Accordingly, an international validation study was undertaken with the primary aim of validating the prognostic role of interim PET using the Deauville 5-point score to evaluate images and with the secondary aim of measuring concordance rates among reviewers using the same 5-point score. This paper focuses on the criteria for interpretation of interim PET and on concordance rates.

AB - At present, there are no standard criteria that have been validated for interim PET reporting in lymphoma. In 2009, an international workshop attended by hematologists and nuclear medicine experts in Deauville, France, proposed to develop simple and reproducible rules for interim PET reporting in lymphoma. Accordingly, an international validation study was undertaken with the primary aim of validating the prognostic role of interim PET using the Deauville 5-point score to evaluate images and with the secondary aim of measuring concordance rates among reviewers using the same 5-point score. This paper focuses on the criteria for interpretation of interim PET and on concordance rates.

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Bleomycin

KW - Consensus

KW - Dacarbazine

KW - Doxorubicin

KW - Hodgkin Disease

KW - Humans

KW - Image Interpretation, Computer-Assisted

KW - Information Storage and Retrieval

KW - Internationality

KW - Multimodal Imaging

KW - Neoplasm Staging

KW - Positron-Emission Tomography

KW - Research Report

KW - Tomography, X-Ray Computed

KW - Vinblastine

U2 - 10.2967/jnumed.112.110890

DO - 10.2967/jnumed.112.110890

M3 - Journal article

C2 - 23516309

SN - 0161-5505

VL - 54

SP - 683

EP - 690

JO - Journal of nuclear medicine : official publication, Society of Nuclear Medicine

JF - Journal of nuclear medicine : official publication, Society of Nuclear Medicine

IS - 5

ER -

International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater